price
RX
NASDAQ · RXRX
Recursion Pharmaceuticals, Inc. Class A Common Stock
Healthcare · Biotechnology
$3.74
Down-$0.15 (-3.86%)
Updated Sep 26, 2026, 5:47 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.83B
- P/E ratio
- -2.94
- Dividend yield
- 0.00%
- 52-week range
- $2.77 – $7.18
- Volume
- 10.48M
- Avg. volume
- 43.4M
Price performance
RXRX price history
1M range · 20 trading sessions · Daily adjusted prices
RXRX closed at $3.74 after 20 trading sessions, up 11.98% for the selected period.
- Last close
- $3.74
- Period change
- +11.98%
- Period low
- $3.16
- Period high
- $4.05
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $3.89 | $3.90 | $3.70 | $3.74 | 10.48M |
| Sep 24, 2026 | $3.65 | $3.90 | $3.61 | $3.89 | 19.34M |
| Sep 23, 2026 | $4.03 | $4.09 | $3.66 | $3.70 | 23.67M |
| Sep 22, 2026 | $4.00 | $4.16 | $3.90 | $4.05 | 40.46M |
| Sep 21, 2026 | $3.92 | $4.015 | $3.83 | $3.97 | 37.73M |
| Sep 18, 2026 | $3.54 | $3.83 | $3.50 | $3.83 | 44.33M |
| Sep 17, 2026 | $3.28 | $3.59 | $3.26 | $3.54 | 28.25M |
| Sep 16, 2026 | $3.26 | $3.31 | $3.16 | $3.19 | 14.81M |
| Sep 15, 2026 | $3.37 | $3.37 | $3.22 | $3.24 | 11.88M |
| Sep 14, 2026 | $3.19 | $3.455 | $3.18 | $3.41 | 17.1M |
| Sep 11, 2026 | $3.21 | $3.25 | $3.15 | $3.20 | 8.03M |
| Sep 10, 2026 | $3.14 | $3.25 | $3.10 | $3.16 | 10.63M |
| Sep 9, 2026 | $3.42 | $3.45 | $3.21 | $3.215 | 14.2M |
| Sep 8, 2026 | $3.58 | $3.59 | $3.43 | $3.44 | 14.99M |
| Sep 4, 2026 | $3.415 | $3.70 | $3.41 | $3.63 | 29.04M |
| Sep 3, 2026 | $3.435 | $3.45 | $3.2901 | $3.44 | 13.75M |
| Sep 2, 2026 | $3.34 | $3.4891 | $3.285 | $3.38 | 14.05M |
| Sep 1, 2026 | $3.34 | $3.38 | $3.2801 | $3.33 | 10M |
| Aug 31, 2026 | $3.305 | $3.41 | $3.25 | $3.40 | 13.91M |
| Aug 28, 2026 | $3.40 | $3.45 | $3.31 | $3.34 | 10.56M |
Latest RXRX news
The latest Smart Investors Daily articles mentioning RXRX.
Stock researchMarket Activity · Insider Trades
Loading stock research…